Cargando…

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data

BACKGROUND: Although chronic non-cancer pain (CNCP) is common among individuals with opioid use disorder (OUD), its impact on buprenorphine treatment retention is unclear. The goal of this study was to use electronic health record (EHR) data to examine the association of CNCP status and 6-month bupr...

Descripción completa

Detalles Bibliográficos
Autores principales:	John, William S., Mannelli, Paolo, Hoyle, Rick H., Greenblatt, Lawrence, Wu, Li-Tzy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Full Length Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948869/ https://www.ncbi.nlm.nih.gov/pubmed/36845986 http://dx.doi.org/10.1016/j.dadr.2022.100048

Ejemplares similares

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder
por: Shadowen, Hannah, et al.
Publicado: (2022)

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims
por: Xu, Kevin Y, et al.
Publicado: (2023)

Disparities in opioid treatment access and retention among women based on pregnancy status from 2006 to 2017
por: Khachikian, Tenie, et al.
Publicado: (2022)

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021
por: del Pozo, Brandon, et al.
Publicado: (2023)

Sex specific effects of buprenorphine on behavior, astrocytic opioid receptor expression and neuroinflammation after pediatric traumatic brain injury in mice
por: Hamood, Yesmine, et al.
Publicado: (2022)

Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability
por: Brooner, Robert K., et al.
Publicado: (2022)

Emergency-department initiated buprenorphine: Impact on quality of life
por: Carroll, Caleb, et al.
Publicado: (2023)

The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022)

Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
por: Winstanley, Erin L., et al.
Publicado: (2022)

An observational study on the use of long acting buprenorphine (Sublocade) and a Tamper resistant PICC for Outpatient IV antibiotic administration in Patients with serious infections and Opioid Use Disorder; The STOP OUD project
por: Pineo, Thomas, et al.
Publicado: (2021)

Feasibility and acceptability of using smartphone-based EMA to assess patterns of prescription opioid and medical cannabis use among individuals with chronic pain
por: Anderson Goodell, Erin M., et al.
Publicado: (2021)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial
por: Janzow, Grace E., et al.
Publicado: (2022)

Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic
por: McFadden, Lisa M.
Publicado: (2023)

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design
por: Roy, Payel Jhoom, et al.
Publicado: (2023)

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort
por: Wang, Xi, et al.
Publicado: (2023)

Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program
por: Ward, Kathleen M., et al.
Publicado: (2022)

Identifying mortality risks in patients with opioid use disorder using brief screening assessment: Secondary mental health clinical records analysis
por: Bogdanowicz, Karolina Magda, et al.
Publicado: (2016)

Medicaid expansion and opioid supply policies to address the opioid overdose crisis
por: Shakya, Shishir, et al.
Publicado: (2022)

Treatment setting among individuals with opioid use and criminal legal involvement, housing instability, or Medicaid insurance, 2015-2021
por: Shearer, Riley D., et al.
Publicado: (2023)

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018
por: Golan, Olivia K., et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder
por: Scherrer, Jeffrey F., et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine‐Derived Phenylazocarboxamides as Novel μ‐Opioid Receptor Ligands
por: Krüll, Jasmin, et al.
Publicado: (2020)

Primary care for opioid use disorder
por: Mannelli, Paolo, et al.
Publicado: (2016)

Electrophysiological Recordings from Embryonic Mouse Motoneurons Cultured on Electrospun Poly-Lactic Acid (PLA) and Polypyrrole-Coated PLA Scaffolds
por: Zuñiga, Esmeralda, et al.
Publicado: (2022)

Effect of Paroxetine on the Neuropathic Pain: A Molecular Study
por: Zarei, Malek, et al.
Publicado: (2020)

Elucidating individual differences in chronic pain and whole person health with allostatic load biomarkers
por: Mickle, Angela M., et al.
Publicado: (2023)

Parenting and childcare responsibilities, harm reduction service engagement, and opioid overdose among women and men who use illicit opioids in New York City
por: Scheidell, Joy D, et al.
Publicado: (2022)

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record
por: Shi, Zongqi, et al.
Publicado: (2022)

Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
por: Khanna, Ish K, et al.
Publicado: (2015)

Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain
por: Pergolizzi Jr, Joseph V, et al.
Publicado: (2019)

Individuals with both higher recent negative affect and physical pain have higher levels of C-reactive protein
por: Graham-Engeland, Jennifer, et al.
Publicado: (2022)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Status of Biofilm-Forming Genes among Jordanian Nasal Carriers of Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
por: Khasawneh, Ashraf I, et al.
Publicado: (2020)

Under-representation of key demographic groups in opioid use disorder trials
por: Rudolph, Kara E., et al.
Publicado: (2022)

COVID-19 impact on opioid overdose after jail release in Massachusetts
por: Friedmann, Peter D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tiobcacdf0u915ok806b4f2hea